BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//The Life Raft Group - ECPv6.15.20//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:The Life Raft Group
X-ORIGINAL-URL:https://liferaftgroup.org
X-WR-CALDESC:Events for The Life Raft Group
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20170312T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20171105T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20180311T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20181104T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20190310T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20191103T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20200308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20201101T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20210314T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20211107T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20220313T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20221106T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:Australia/Melbourne
BEGIN:STANDARD
TZOFFSETFROM:+1100
TZOFFSETTO:+1000
TZNAME:AEST
DTSTART:20200404T160000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+1000
TZOFFSETTO:+1100
TZNAME:AEDT
DTSTART:20201003T160000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+1100
TZOFFSETTO:+1000
TZNAME:AEST
DTSTART:20210403T160000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+1000
TZOFFSETTO:+1100
TZNAME:AEDT
DTSTART:20211002T160000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+1100
TZOFFSETTO:+1000
TZNAME:AEST
DTSTART:20220402T160000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+1000
TZOFFSETTO:+1100
TZNAME:AEDT
DTSTART:20221001T160000
END:DAYLIGHT
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20210512T120000
DTEND;TZID=America/New_York:20210512T130000
DTSTAMP:20260504T215137
CREATED:20210420T151025Z
LAST-MODIFIED:20210420T151025Z
UID:10000138-1620820800-1620824400@liferaftgroup.org
SUMMARY:Management of Metastatic GIST
DESCRIPTION:What to Expect When a Tumor Has Spread\nWhile surgery is the backbone of treatment for localized GIST\, in the context of metastatic disease\, treatment generally relies on medical therapy with tyrosine kinase inhibitors such as imatinib. Surgery is used predominantly to optimize their efficacy. This webinar will review options for therapy when patients are diagnosed with metastatic disease at the time of their initial diagnosis\, during observation after initial resection of a GIST\, and when metastatic GIST is resistant to imatinib. We will discuss the role that mutational status and drug toxicities may play in determining the optimal therapy for individual patients. \nREGISTERAbout the Presenter:\nDr. Aimee Crago\, Surgical Oncologist\nMemorial Sloan Kettering Cancer Center \nDr. Crago earned her PhD at the University of Cambridge as a British Marshall Scholar and her MD in the Harvard-MIT Division of Health Sciences and Technology before training in surgery and surgical oncology at Georgetown University Medical Center and Memorial Sloan Kettering Cancer Center. She joined the MSKCC faculty in 2010 as member of the Gastric and Mixed Tumor Service and the Sarcoma Disease Management Team\, and now serves as Associate Attending Surgeon. She is an active participant in the care of patients with soft tissue sarcoma\, GIST and desmoid-type fibromatosis and coordinates a translational science research program that focuses on understanding the molecular drivers of sarcomas and how genomic aberrations in these tumors can inform patient care. Her work has been funded by the National Cancer Institute\, the Food and Drug Administration\, the American Society of Clinical Oncology\, the American College of Surgeons\, and the American Cancer Society among others. Dr. Crago is committed to educating others regarding sarcoma biology and patient care; as such\, she trains clinical and research fellows at Memorial Sloan Kettering\, is a Gerstner Sloan Kettering Graduate School Special Contributing Faculty Member\, and works as chair of the Society for Surgical Oncology Sarcoma Disease Site Working Group.   
URL:https://liferaftgroup.org/event/management-of-metastatic-gist/
CATEGORIES:Education,Events
ORGANIZER;CN="Sara Rothschild":MAILTO:srothschild@liferaftgroup.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20210429T120000
DTEND;TZID=America/New_York:20210429T130000
DTSTAMP:20260504T215137
CREATED:20210408T134459Z
LAST-MODIFIED:20210408T134855Z
UID:10000137-1619697600-1619701200@liferaftgroup.org
SUMMARY:Genetics of GIST
DESCRIPTION:Risks\, Management\, and What to Know for You and Your Family\nIn this webinar\, we will review what is known about the hereditary causes behind GISTs\, current genetic testing options and results\, how this information affects screening and management\, and implications for one’s family. \n\nREGISTER\n \nPresenters:\nLindsay Kipnis received her MS in Genetic Counseling from Brandeis University in 2013. After graduating she worked in oncology at Women & Infants Hospital in Rhode Island. She joined the Center for Cancer Genetics and Prevention at DFCI in 2014. Lindsay is focused on ensuring that all ovarian cancer patients receive the genetic counseling and testing that is recommended. She also sees a variety of adult patients with personal and family histories of cancer. \n\n \nBecca Vanderwall is a licensed and certified genetic counselor currently practicing at Dana-Farber Cancer Institute in the pediatric cancer genetics risk program. She previously worked in neurometabolics and mitochondrial disease at Boston Children’s Hospital. She earned her MS in Genetic Counseling and MPH in Public Health Genetics from the University of Pittsburgh in 2016. Her special interests include public health research and policy\, health disparities and equity\, hereditary brain tumor risk\, and family dynamics and communication.
URL:https://liferaftgroup.org/event/genetics-of-gist/
CATEGORIES:Events
ORGANIZER;CN="Sara Rothschild":MAILTO:srothschild@liferaftgroup.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20210224T120000
DTEND;TZID=America/New_York:20210224T120000
DTSTAMP:20260504T215137
CREATED:20210203T201450Z
LAST-MODIFIED:20210208T141853Z
UID:10000132-1614168000-1614168000@liferaftgroup.org
SUMMARY:Finding Biomarkers that Cause GIST
DESCRIPTION:From Research to Clinical Application\nEvery GIST patient is unique based on their biology and what treatment to which they will potentially respond. \nDr. Lori Rink\, Fox Chase Cancer Center\, and Dr. Inga-Marie Schaefer\, Brigham & Women’s Hospital\, are two researchers who are making discoveries in their respective laboratories to uncover the unique biomarkers in GIST that will be future drug targets. \nDr. Margaret von Mehren\, Fox Chase Cancer Center\, will moderate the webinar and help the audience understand why these important discoveries in the lab are important to clinicians. This concept of translational medicine is an important field as it helps bring advances into the clinic that can directly impact the survival of GIST patients. \nREGISTERAbout the Presenters\nLori Rink\, PhD\nAssistant Professor\, Molecular Therapeutics\, Fox Chase Cancer Center. Dr. Rink studied at the Biology at the University of Scranton  and  received her doctorate in  for a Doctorate in Molecular Biology from Temple University followed by a post-doctoral fellowship at Fox Chase Cancer Center.  She is an Assistant Professor in the Molecular Therapeutic program. Along with Dr. von Mehren\, two graduate students\, and a post-doctoral fellow\, Dr. Rink’s lab is dedicated to investigating why some GIST patients eventually develop a resistance to Gleevec\, discovering combinations of drugs that will attack GIST\, and identifying markers that could predict how patients will respond to Gleevec. \nInga-Marie Schaefer\, MD\nAssociate Pathologist\, Brigham & Women’s Hospital\, Instructor in Pathology\, Harvard Medical School\nDr. Schaefer is an instructor at the Department of Pathology at Brigham and Women’s Hospital\, Harvard Medical School in Boston\, MA. After graduating with an M.D. degree from Georg-August-University Goettingen in Germany\, she trained in Anatomic Pathology in Germany and at Brigham and Women’s Hospital. Her post-doctoral research in Dr. Jonathan Fletcher’s translational sarcoma laboratory focused on characterizing mechanisms of genomic progression in GIST/sarcoma\, combining diagnostics\, biology\, and genetics. Dr. Schaefer is now evaluating mechanisms of incremental cell cycle dysregulation in GIST progression. \n\nAbout the Moderator\nMargaret von Mehren\, MD\nAssociate Professor\, Director of Sarcoma\, Fox Chase Cancer Center\nDr. von Mehren matriculated at Georgetown University in Washington\, DC\, where she majored in Biology and minored in Philosophy\, and graduating in 1985 with honors. She received her medical degree from Albany Medical College in Albany\, NY. Dr. von Mehren completed an internship and residency at New York University Medical Center in New York before moving to Philadelphia for her fellowship in medical oncology at the Fox Chase Cancer Center and Temple University. After completing fellowship\, Dr. von Mehren joined the faculty of the department of Medical Oncology at Fox Chase Cancer Center where she remains today as and Associate Professor and the director of the Sarcoma program. She is a member of the NCCN panel for soft tissue sarcomas and GIST task force\, as well as the Intergroup GIST Task force. She also volunteers at the NIH Pediatric Wildtype GIST clinic biannually.
URL:https://liferaftgroup.org/event/finding-biomarkers-that-cause-gist/
CATEGORIES:Education,Events
ORGANIZER;CN="Sara Rothschild":MAILTO:srothschild@liferaftgroup.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20210211T120000
DTEND;TZID=America/New_York:20210211T120000
DTSTAMP:20260504T215137
CREATED:20201103T133157Z
LAST-MODIFIED:20210124T180346Z
UID:10000093-1613044800-1613044800@liferaftgroup.org
SUMMARY:LRG Webcast Series: hPPGL Syndrome - a Misnomer with Consequences
DESCRIPTION:Dr. Annes will review the hPPGL Syndrome with particular focus on the underlying genetics basis and related tumor risks. He will review the benefits/limitations of genetic testing and pre-symptomatic screening\, including his personal experience directing Stanford’s Hereditary Neuroendocrine Neoplasia Clinic. Finally\, he will discuss opportunities for advancing hPPGL care and ongoing research. \nREGISTERPresenter:\nJustin Annes\, MD\, PhD\nAssociate Professor\, Stanford Department of Medicine \nDr. Annes is an Associate Professor in Stanford’s Department of Medicine and a Faculty Fellow in Stanford’s Chemistry\, Engineering & Medicine for Human Health Institute (ChEM-H). He obtained his BS from Haverford College (1996)\, MD PHD from New York University (1996) and trained in Internal Medicine\, Clinical Genetics and Chemical Biology at Brigham and Women’s Hospital / Harvard University (2011). Dr. Annes is director and founder of Stanford’s Hereditary Neuroendocrine Tumor Clinic (2012) which focuses on the longitudinal care of patients and families with inherited endocrine tumor syndromes\, primarily hPPGL\, MEN1 and MEN2. He participates in several neuroendocrine-focused patient advocacy / research foundations including The Pheo Para Alliance\, Neuroendocrine Tumor Research Foundation and the NIH Pediatric Wildtype GIST Clinic. His NIH-funded research program is positioned at the interface of endocrine pathophysiology\, synthetic chemistry and hereditary disease. The organizing principle of his research program is to harness the power of chemistry\, human tissue samples and animal disease models to deliver fundamental biologic insights and develop novel therapeutic leads for the treatment of endocrine disorders.
URL:https://liferaftgroup.org/event/lrg-webcast-hppgl-syndrome/
CATEGORIES:Education,Events
ATTACH;FMTTYPE=image/jpeg:https://liferaftgroup.org/wp-content/uploads/2020/11/annes1.jpg
ORGANIZER;CN="Sara Rothschild":MAILTO:srothschild@liferaftgroup.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Australia/Melbourne:20210205T110000
DTEND;TZID=Australia/Melbourne:20210205T110000
DTSTAMP:20260504T215137
CREATED:20210111T201224Z
LAST-MODIFIED:20210113T134856Z
UID:10000094-1612522800-1612522800@liferaftgroup.org
SUMMARY:Australian GISTers Virtual Meet & Greet
DESCRIPTION:Please be aware of the time difference: This webinar takes place on Feb 4th at 7pm ET for the US and Feb 5th at 11 am Melbourne time.) \nPlease join us for a Virtual Meet & Greet with our new Australian GIST Representatives Shari Reid and Amy Kenworthy! GIST patients and family members are welcome to join this virtual get together to connect as well as meet one of the leading GIST experts in Australia – Dr. John Zalcberg from Monash University. \nREGISTERPresenters\nShari Reid\, Victoria \nShari Reid\, formerly a Systems Administrator in Health & Safety\, is currently a proud\, full-time mum to son Robbie. Though she’s living in regional Victoria with her husband\, Glenn\, and son\, Shari was born in the U.S. and her family moved to Australia when she was a baby. \n\nAmy Kenworthy\, Gold Coast \nProfessor Amy Kenworthy\, also born in the U.S.\, was raised in Massachusetts and immigrated to Queensland\, Australia\, after finishing her PhD in 1999. She and her husband\, George\, are both professors at Bond University on the Gold Coast. They have two teens\, Bryce\, 13\, and Mariel\, 17. \n\nRead more about these amazing GISTers! \n\nDr. John  Zalcberg\nProfessor Zalcberg is currently the Head of the Cancer Research Program as well as NHMRC (MRFF) Practitioner Fellow in the School of Public Health and Preventive Medicine at Monash University – currently overseeing the establishment and activities of clinical quality registries across various tumour types. He is also the inaugural Tony Charlton Chair of Oncology at Alfred Health as well.\nYou can view this presentation on OncLive – Dr. Zalcberg on the Management of Patients With GIST
URL:https://liferaftgroup.org/event/australian-gisters-virtual-meet-greet/
CATEGORIES:Events,International
ORGANIZER;CN="Sara Rothschild":MAILTO:srothschild@liferaftgroup.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20201026T120000
DTEND;TZID=America/New_York:20201026T120000
DTSTAMP:20260504T215138
CREATED:20201002T183013Z
LAST-MODIFIED:20201022T161543Z
UID:10000089-1603713600-1603713600@liferaftgroup.org
SUMMARY:Women in Sarcoma: Case Presentations
DESCRIPTION:Case Presentations\nOctober 26\, 12PM ET \nPlease join us for the second webcast of our Women in Sarcoma series. The Life Raft Group has developed the Women in Sarcoma program in recognition of the many women sarcoma specialists that engage with the sarcoma patient community and focus on educating and advocating on behalf of those living with sarcoma. \nThis panel features three women sarcoma experts presenting unique case studies that they have encountered in their practices. Panelists will interact with each other about these case studies\, and participants will gain meaningful insight into how these experts diagnose and treat sarcoma patients\, and how they collaborate with colleagues toward the goal of achieving positive outcomes for these challenging cases. \n\nIf you have questions about this panel or about registration\, please contact Sara Rothschild\, VP Program Services \n\nPlease join us for this interactive session with women leading the field of sarcoma!\n\nREGISTEROur Panel of Experts\n \n\nVaia Florou\, MD\nOncologist\nUniversity of Utah\nHuntsman Cancer Center\n \n\nCiara Kelly\, MBBCh BAO\nOncologist\nMemorial Sloan Kettering\nCancer Center\n \n\n\nSandra R. Brackert\, NP\nNurse Practitioner\nRonald Reagan UCLA\nMedical Center
URL:https://liferaftgroup.org/event/women-in-sarcoma-case-presentations/
CATEGORIES:Education,Research,Webcast
ATTACH;FMTTYPE=image/jpeg:https://liferaftgroup.org/wp-content/uploads/2020/10/Women-In-Sarcoma-2.jpg
ORGANIZER;CN="Sara Rothschild":MAILTO:srothschild@liferaftgroup.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20201020T120000
DTEND;TZID=America/New_York:20201020T120000
DTSTAMP:20260504T215138
CREATED:20200909T152729Z
LAST-MODIFIED:20200916T162445Z
UID:10000087-1603195200-1603195200@liferaftgroup.org
SUMMARY:LRG Webcast: Genetics 101
DESCRIPTION:With the alphabet soup of terms and genes that cancer patients tend to hear during diagnosis\, it takes some time to really understand what these terms mean. \nIn her Genetics 101 webcast\, Dr. Raygada will unravel the DNA terms and seek to empower patients by helping them understand the genetic basis of their conditions so that they may decrease the risks associated with the mutations and tumors they carry. \nREGISTERAbout the presenter\nMargarita Raygada\, PhD\, Oncology Genetic Counselor \nDr. Raygada’s doctorate degree is in Medical Science from the Uniformed Services University of the Health Sciences/Naval Hospital\, Bethesda\, Maryland. Her Master’s degree is in Human Genetics and Genetic Counseling\, Georgetown University Hospital (GUH) in Washington\, D.C.\, with two post-doctoral fellowships: Molecular Biology at The Johns Hopkins Hospital in Baltimore\, and Cancer Genetics at GUH. Research Focus: Cancer genetics is my passion. I am interested in delineating the genetic changes in rare tumors and identifying associated phenotypes that may lead to common pathways and therefore improved outcomes for cancer patients. But most importantly I hope to empower patients by helping them understand the genetic basis of their conditions\, and by educating them on how they can use this information to manage their cancer so that they may decrease the risks associated with the mutations and tumors they carry.
URL:https://liferaftgroup.org/event/lrg-webcast-genetics-101/
CATEGORIES:Education,Webcast
ATTACH;FMTTYPE=image/jpeg:https://liferaftgroup.org/wp-content/uploads/2020/08/raygada-event.jpg
ORGANIZER;CN="Sara Rothschild":MAILTO:srothschild@liferaftgroup.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200924T140000
DTEND;TZID=America/New_York:20200924T140000
DTSTAMP:20260504T215138
CREATED:20200911T003207Z
LAST-MODIFIED:20200911T122756Z
UID:10000088-1600956000-1600956000@liferaftgroup.org
SUMMARY:Women in Sarcoma: Cancer Warriors
DESCRIPTION:An Interactive Multidisciplinary Panel of Experts\nSeptember 24th\, 2020 at 2pm \nThe Life Raft Group has developed the Women in Sarcoma program in recognition of the many women sarcoma specialists that engage with our organization and our patient and caregiver community to educate and advocate on behalf of those living with sarcoma. Our goal is to highlight women in the sarcoma medical profession that make a difference in patients’ lives\, and to inspire the community to hear stories and perspectives of women’s role in oncology. \nThe September webcast will feature an interactive panel of women sarcoma experts sharing their expertise as powerful advocates working on behalf of those living with sarcoma. Please join us for this interactive session with women leading the field of sarcoma! \nIf you have questions about this panel or about registration\, please contact Sara Rothschild\, VP Program Services \n\nREGISTEROur Panel of Experts\n[table “61” not found /]
URL:https://liferaftgroup.org/event/women-in-sarcoma-cancer-warriors/
CATEGORIES:Events
ORGANIZER;CN="Sara Rothschild":MAILTO:srothschild@liferaftgroup.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200616T120000
DTEND;TZID=America/New_York:20200616T130000
DTSTAMP:20260504T215138
CREATED:20200512T205723Z
LAST-MODIFIED:20200515T142935Z
UID:10000066-1592308800-1592312400@liferaftgroup.org
SUMMARY:LRG Webcast Series: GIST: How to Understand your Pathology Report
DESCRIPTION:In this webinar\, we will be discussing how to interpret your pathology report. We will cover interpretation of all parts of a pathology report\, beginning with understanding the final diagnosis and diagnostic comment. We will then review the results and significance of performed ancillary testing\, including immunohistochemistry\, prognostic biomarker testing\, and molecular testing. We will end by discussing how the aforementioned pathology report data affects clinical surgical and therapeutic decision-making. \nREGISTERAbout the Presenters:\nKelsey McHugh\, M.D.\nGastrointestinal\, Hepatic\, and Pancreatobiliary Pathology Fellow\nRobert J. Tomsich Pathology & Laboratory Medicine Institute\nCleveland Clinic \nKelsey McHugh\, MD is a board certified anatomic and clinical pathologist\, with cytopathology subspecialty certification\, who is currently completing gastrointestinal\, hepatic\, and pancreatobiliary pathology subspecialty training. She anticipates graduating from the Cleveland Clinic Gastrointestinal\, Hepatic\, and Pancreatobiliary Pathology Fellowship in June 2020\, after which she will remain at the Cleveland Clinic as a staff pathologist beginning July 2020.
URL:https://liferaftgroup.org/event/understand-your-pathology-report/
CATEGORIES:Education,Webcast
ORGANIZER;CN="Sara Rothschild":MAILTO:srothschild@liferaftgroup.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200514T140000
DTEND;TZID=America/New_York:20200514T150000
DTSTAMP:20260504T215138
CREATED:20200421T143006Z
LAST-MODIFIED:20200520T122214Z
UID:10000061-1589464800-1589468400@liferaftgroup.org
SUMMARY:LRG Webcast Series: GIST\, TKI Treatment & Effects on Memory
DESCRIPTION:Cancer-related cognitive impairment\, or CRCI\, is common among certain cancer survivors\, for example\, individuals with breast cancer. CRCI usually presents as mild to moderate problems with memory and attention and can even persist long after cancer treatment has ended. Many have called this “chemobrain” or “chemofog” but research over the past three decades indicates that cancer itself\, genetic vulnerabilities and treatments other than chemotherapy can lead to persistent CRCI. \nSimilar to patients treated with chemotherapy\, patients with GIST are complaining about long-term side effects of Gleevec therapy with respect to cognitive function (“Gleevec brain”). Nevertheless\, very little is known about CRCI in cancer patients who are being treated with tyrosine kinase inhibitors (TKIs)\, like Gleevec\, including patients with GIST. \nThis discussion will review CRCI in general\, and how a person who is being treated for GIST could be affected. We will also talk about strategies that can help ameliorate CRCI and discuss our new research on CRCI and GIST. Finally\, in light of the COVID-19 pandemic\, we will give advice on how cancer survivors can best cope with and care for themselves during this unusual global health event. \nSEE The RecapAbout the Presenters:\nAnette Duensing\, M.D.\nAssociate Professor of Pathology\nUniversity of Pittsburgh School of Medicine \nAnette Duensing holds an M.D. degree from the University of Hannover School of Medicine\, Germany\, and is an Associate Professor of Pathology at the University of Pittsburgh School of Medicine as well as Member of the Cancer Therapeutics Program at the UPMC Hillman Cancer Center. Her research focuses on gastrointestinal stromal tumors (GISTs) as well as other sarcomas with the goal of identifying novel therapeutic approaches. Recently\, Dr. Duensing has teamed up with Dr. Robert Ferguson at UPMC HCC to study cognitive impairment in GIST patients treated with Gleevec and other tyrosine kinase inhibitors. Dr. Duensing is the author of nearly 70 original articles\, reviews and book chapters. Her research has been supported by the American Cancer Society\, the Sarcoma Foundation of America\, the GIST Cancer Research Fund and the Life Raft Group. \nRobert J. Ferguson\, Ph.D.\nAssistant Professor of Medicine with the Division of Hematology/Oncology\nUniversity of Pittsburgh School of Medicine and Hillman Cancer Center \nDr. Ferguson is a clinical psychologist and Assistant Professor of Medicine with the Division of Hematology/Oncology at the University of Pittsburgh School of Medicine and Hillman Cancer Center. His clinical and research interests are the treatment of cognitive effects of cancer\, cancer survivorship and palliative care. He is the author of numerous peer reviewed research articles and book chapters on treatment of cancer-related cognitive dysfunction and other topics related to the field of behavioral medicine. His research has been funded by grants from the National Cancer Institute\, NIH Office of Research on Women’s Health\, and the Lance Armstrong Foundation. \n\n \nDisclaimer:\nWe cannot provide individual medical advice during this webcast. Information provided in this webcast is not intended as a substitute for your physician’s guidance and care.
URL:https://liferaftgroup.org/event/lrg-webcast-series-treatment-effects-memory/
CATEGORIES:Education,Events
ORGANIZER;CN="Sara Rothschild":MAILTO:srothschild@liferaftgroup.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200323T120000
DTEND;TZID=America/New_York:20200323T130000
DTSTAMP:20260504T215138
CREATED:20200311T125440Z
LAST-MODIFIED:20200414T152639Z
UID:10000057-1584964800-1584968400@liferaftgroup.org
SUMMARY:LRG Webcast Series: New Treatment Options for Advanced GIST & Concerns about the Coronavirus
DESCRIPTION:Avapritinib is a medication used for the treatment of tumors due to one specific rare mutation: It is specifically intended for adults with unresectable or metastatic gastrointestinal stromal tumor that harbor a platelet-derived growth factor receptor alpha exon 18 mutation. \nRipretinib is an investigational broad-spectrum KIT and PDGFRα inhibitor in development for the treatment of patients with advanced gastrointestinal stromal tumors (GIST). \nDuring this webcast presentation\, Dr. Michael Heinrich will discuss these two new treatment options for advanced GIST. Dr. Heinrich will explain how each of these drugs works to target mutations for which there has previously been no targeted treatment. He will also address key questions for GIST patients concerning the coronavirus. \nListen to the recapAbout the Presenter:\n \nMichael Heinrich\, M.D.\nProfessor of Medicine and Cell/Developmental Biology\nOHSU School of Medicine \nDr. Heinrich earned his medical degree from Johns Hopkins School of Medicine in Baltimore and completed both his residency training and fellowship in hematology/medical oncology at OHSU. \nDr. Heinrich’s research\, like much of the work at the Knight Cancer Institute\, revolves around a basic\, yet complex premise. You have to understand what is broken in order to fix it. That’s why Dr. Heinrich is intently focused on identifying the molecular targets that cause cancer\, which is essential to the development of better and less toxic therapies. He is recognized internationally for groundbreaking research discoveries that have improved care for patients with gastrointestinal stromal tumors\, and his research has implications for many types of cancer. \n\nDisclaimer:\nWe cannot provide individual medical advice during this webcast. Information provided in this webcast is not intended as a substitute for your physician’s guidance and care.
URL:https://liferaftgroup.org/event/lrg-webcast-series-new-treatment-options-for-advanced-gist/
ATTACH;FMTTYPE=image/png:https://liferaftgroup.org/wp-content/uploads/2020/03/heinrich-event-v2.png
ORGANIZER;CN="Sara Rothschild":MAILTO:srothschild@liferaftgroup.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20190911T140000
DTEND;TZID=America/New_York:20190911T150000
DTSTAMP:20260504T215138
CREATED:20190725T201333Z
LAST-MODIFIED:20190917T152156Z
UID:10000037-1568210400-1568214000@liferaftgroup.org
SUMMARY:LRG Webcast Series: Updates on the Temozolomide Trial
DESCRIPTION:The Temozolomide Trial for SDH-deficient GIST Patients\nGIST is becoming increasingly diverse. SDH-deficient GIST and paragangliomas often occur in adolescents and young adults. Since these SDH mutations are germline\, multiple generations of family members are affected.\n\nDr. Jason Sicklick of Moores Cancer Center at the University of California San Diego will present a webcast detailing the Phase II study of Temozolomide (TMZ) in advanced SDH-mutant/deficient GIST\, a new study available to patients with SDH-deficient GIST.\n\n\nListen to the Webinar\n\nAbout the Presenter:\nJason K. Sicklick\, MD\, FACS\, is an Associate Professor of Surgery\, Division of Surgical Oncology; and Co-Director\, Biorepository and Tissue Technology Shared Resource\, Moores Cancer Center at the University of California\, San Diego\, UC San Diego Health Sciences. \n  \n  \n  \n\nTechnical Tips to Join Meeting:\n\nThis is a web-only meeting\, accessed only by your internet connection. Participants are encouraged to use the web link automatically provided after registration and to use computer speakers (and/or headsets if available) to hear the audio portion of the meeting. Please log in at least ten minutes prior to the start of the webinar.\nPlease ensure you have an updated version of Adobe Flash Player (Google Chrome has Flash built-in).\nIf you are using a mobile device or tablet\, in order to view and hear the conference\, download the ReadyTalk App from your App store.\n\n\nDisclaimer:\nWe cannot provide individual medical advice during this webcast. Information provided in this webcast is not intended as a substitute for your physician’s guidance and care.
URL:https://liferaftgroup.org/event/lrg-webcast-series-updates-on-the-temozolomide-trial/
CATEGORIES:Education,Webcast
ATTACH;FMTTYPE=image/jpeg:https://liferaftgroup.org/wp-content/uploads/2019/07/sicklick-temozolomide-webcast.jpg
ORGANIZER;CN="Sara Rothschild":MAILTO:srothschild@liferaftgroup.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20190909T120000
DTEND;TZID=America/New_York:20190909T130000
DTSTAMP:20260504T215138
CREATED:20190816T164240Z
LAST-MODIFIED:20190911T172010Z
UID:10000040-1568030400-1568034000@liferaftgroup.org
SUMMARY:LRG Webcast Series: Medicare 101
DESCRIPTION:Medicare 101: An Overview of the A\, B\, C\, and Ds of Medicare\n\nThe A B C’s of Medicare: Everything you need to know\nWhat is Medicare\, am I eligible and how do I enroll?\nWhat does Medicare cover?\nHow much does it cost?\nWhich path should I choose – Medigap Supplement Insurance or Medicare Advantage Plan?\nHow about Prescription Drug coverage?\nFinancial Assistance Programs to help with Medicare costs\n\nRECAP HERE\n\nThere will be a 15 minute Q & A at the end of the presentation. \nAbout the Presenter:\nKathy Sarmiento has been working for the Alliance for Aging for fifteen years.  The Alliance for Aging is the non-profit Area Agency on Aging for Miami-Dade and Monroe Counties in Florida. In her role as the SHINE Liaison\, Kathy manages the all aspects of the free SHINE Medicare counseling program. Kathy also manages the Benefits Enrollment Center at the Alliance for Aging. The Benefits Enrollment Center is a grant from the National Council on Aging to provide five core benefits to financially needy Medicare beneficiaries. Those five core benefits are Medicaid\, food assistance\, assistance paying for Medicare\, Prescription Drug assistance and assistance paying the light bill. \n\n\nTechnical Tips to Join Meeting:\n\nThis is a web-only meeting\, accessed only by your internet connection. Participants are encouraged to use the web link automatically provided after registration and to use computer speakers (and/or headsets if available) to hear the audio portion of the meeting. Please log in at least ten minutes prior to the start of the webinar.\nPlease ensure you have an updated version of Adobe Flash Player (Google Chrome has Flash built-in).\nIf you are using a mobile device or tablet\, in order to view and hear the conference\, download the ReadyTalk App from your App store.\n\n\nDisclaimer:\nWe cannot provide individual medical advice during this webcast. Information provided in this webcast is not intended as a substitute for your physician’s guidance and care.
URL:https://liferaftgroup.org/event/lrg-webcast-series-medicare-101/
CATEGORIES:Webcast
ATTACH;FMTTYPE=image/jpeg:https://liferaftgroup.org/wp-content/uploads/2019/08/sarmiento-medicare-webcast.jpg
ORGANIZER;CN="Sara Rothschild":MAILTO:srothschild@liferaftgroup.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20190808T140000
DTEND;TZID=America/New_York:20190808T150000
DTSTAMP:20260504T215138
CREATED:20190711T153122Z
LAST-MODIFIED:20190814T174529Z
UID:10000035-1565272800-1565276400@liferaftgroup.org
SUMMARY:LRG Webcast Series: When to Consider Surgery
DESCRIPTION:This webcast will address the issues surrounding the decision to have an operation. Most GIST patients will see a surgeon at some point during their treatment. The decision to consider surgical options depends on a number of factors such as tumor location\, tumor size\, tumor number\, response to drug therapy\, and risk of recurrence. \nDr. Jason Sicklick from Moores Cancer Center at the University of California San Diego will discuss situations when surgical management may be appropriate for managing localized\, regionally advanced and metastatic GIST. \n\nListen To The Webcast\n\nThere will be a 15 minute Q & A at the end of the presentation.\n \nAbout the Presenter:\nJason K. Sicklick\, MD\, FACS\, is an Associate Professor of Surgery\, Division of Surgical Oncology; and Co-Director\, Biorepository and Tissue Technology Shared Resource\, Moores Cancer Center at the University of California\, San Diego\, UC San Diego Health Sciences. \n  \n  \n  \n\nTechnical Tips to Join Meeting:\n\nThis is a web-only meeting\, accessed only by your internet connection. Participants are encouraged to use the web link automatically provided after registration and to use computer speakers (and/or headsets if available) to hear the audio portion of the meeting. Please log in at least ten minutes prior to the start of the webinar.\nPlease ensure you have an updated version of Adobe Flash Player (Google Chrome has Flash built-in).\nIf you are using a mobile device or tablet\, in order to view and hear the conference\, download the ReadyTalk App from your App store.\n\n\nDisclaimer:\nWe cannot provide individual medical advice during this webcast. Information provided in this webcast is not intended as a substitute for your physician’s guidance and care.
URL:https://liferaftgroup.org/event/lrg-webcast-series-when-to-consider-surgery/
CATEGORIES:Events
ATTACH;FMTTYPE=image/jpeg:https://liferaftgroup.org/wp-content/uploads/2019/07/sicklick-surgery-webcast.jpg
ORGANIZER;CN="Sara Rothschild":MAILTO:srothschild@liferaftgroup.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20190618T120000
DTEND;TZID=America/New_York:20190618T130000
DTSTAMP:20260504T215138
CREATED:20190605T174046Z
LAST-MODIFIED:20190814T174912Z
UID:10000028-1560859200-1560862800@liferaftgroup.org
SUMMARY:Symptom and Side Effect Management
DESCRIPTION:Listen to the Webcast\n \nGIST and its treatment can cause a variety of symptoms. Adequate management of symptoms can improve a patient’s quality of life. Proper management can also allow the patient to remain on treatment without a decrease in dosage\, interruption of treatment\, or even the discontinuation of treatment. Staying on treatment as prescribed gives patients the best chance of a good outcome and in some cases has been shown to improve survival rates. \nIn this webcast\, Dr. Lori Williams\, Associate Professor in the Department of Symptom Research at MD Anderson Cancer Center\, will review common symptoms associated with GIST and some of its treatments. She will present methods patients can use to self-manage symptoms as well as how to discuss and when to report symptoms to health care providers. \nPete Knox\, LRG Senior Director of Research\, will also share an update on our interactive side effects management platform\, SideEQ. This platform is a great tool to allow patients to optimize their overall health by learning and sharing tips with others on how to manage side effects. To learn more\, visit MySideEQ.org \nThere will be a 15 minute Q & A at the end of the presentation. \nAbout the Presenters:\nDr. Lori Williams is an Associate Professor in the Department of Symptom Research at The University of Texas MD Anderson Cancer Center and an Advanced Oncology Certified Nurse. She has worked in oncology nursing for more than 35 years. She is a member of the executive board of the Patient Advocate and National Patient Advocate Foundations and a secretary-treasurer of the Board of the Oncology Nursing Certification Corporation. Her current work at MD Anderson involves the study of symptoms of cancer and cancer treatment. She is currently working with leadership at MD Anderson to institute routine clinical symptom monitoring for all patients. \nAs Senior Director of Research\, Pete Knox is a key member of the Real World Evidence Team\, utilizing his analytic skills to provide strategic oversight of the Life Raft Group’s research and data platforms. In this role\, he identifies and develops potential collaborations with institutions and organizations that utilize data to advance research\, with the goal of improving overall survival and quality of life for GIST patients. \n\nTechnical Tips to Join Meeting:\n\nThis is a web only meeting\, accessed only by your internet connection. Participants are encouraged to use the web link automatically provided after registration and to use computer speakers (and/or headsets if available) to hear the audio portion of the meeting. Please log in at least ten minutes prior to the start of the webinar.\nPlease ensure you have an updated version of Adobe Flash Player (Google Chrome has Flash built in).\nIf you are using a mobile device or tablet\, in order to view and hear the conference\, download the ReadyTalk App from your App store.\n\n\nDisclaimer:\nWe cannot provide individual medical advice during this webcast. Information provided in this webcast is not intended as a substitute for your physician’s guidance and care.
URL:https://liferaftgroup.org/event/symptom-and-side-effect-management/
CATEGORIES:Events
ATTACH;FMTTYPE=image/jpeg:https://liferaftgroup.org/wp-content/uploads/2019/06/williams.jpg
ORGANIZER;CN="Sara Rothschild":MAILTO:srothschild@liferaftgroup.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20190508T130000
DTEND;TZID=America/New_York:20190508T130000
DTSTAMP:20260504T215138
CREATED:20190423T160916Z
LAST-MODIFIED:20190423T161403Z
UID:10000004-1557320400-1557320400@liferaftgroup.org
SUMMARY:Ask the Experts LIVE
DESCRIPTION:Want to know more about GIST?\nDo you have some burning questions to ask GIST experts?\n\nMembers of the LRG GIST Global Expert Surveillance Team\nwill be at the LRG offices on May 8th at 1:00 pm ET for an\nAsk the Experts LIVE event to be broadcast on YouTube Live.\n\n\n\n \nDr. Gary Schwartz\nColumbia University Irving Medical Center \n\nDr. Jason Sicklick\nMoores Cancer Center\, University of California\, San Diego\n\n\nDr. Jonathan Trent\nSylvester Comprehensive Cancer Center \n\nRegister\n\n\n\n\nWe welcome you to submit your questions ahead of time.\nQuestions can be emailed to Sara Rothschild at srothschild@liferaftgroup.org.\nViewers can also ask questions live during the event.\n\n\nDisclaimer:\nWe cannot provide individual medical advice during this live event. Information provided is not intended as a substitute for your physician’s guidance and care.
URL:https://liferaftgroup.org/event/ask-the-experts-live/
LOCATION:You Tube Live
CATEGORIES:Education,Events
ATTACH;FMTTYPE=image/jpeg:https://liferaftgroup.org/wp-content/uploads/2019/04/ask-the-experts-live-eventpg.jpg
ORGANIZER;CN="Sara Rothschild":MAILTO:srothschild@liferaftgroup.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20190503T130000
DTEND;TZID=America/New_York:20190503T140000
DTSTAMP:20260504T215138
CREATED:20190418T143423Z
LAST-MODIFIED:20190507T155606Z
UID:10000019-1556888400-1556892000@liferaftgroup.org
SUMMARY:LRG Webcast: Genetic Testing and SDHx Mutations
DESCRIPTION:Genetic Testing and SDHx Mutations:\nWhat do they have to do with PGL/GIST/Pheos?\nLISTEN TO WEBCAST\n\nThis webcast will highlight how SDHx mutations impact risks for paraganglioma\, pheochromocytomas\, and GIST. We’ll discuss why genetic testing is helpful for any diagnosis of GIST\, paraganglioma or pheochromocytoma\, and what the SDHx genes have to do with tumor risk. We’ll discuss what types of tumors are associated with mutations in the SDHx genes\, and how different SDHx genes (SDHA\, SDHB\, SDHC\, SDHD\, SDHAF2) have different tumor and location risks. This webcast will highlight recommendations for screening and current research initiatives for SDHx and paragangliomas.\n\nAbout the Presenter:\nSamantha Greenberg is a board-certified genetic counselor who oversees the SDHx clinic and specializes in paraganglioma research at Huntsman Cancer Institute. She graduated with a Master’s Degree in Human Genetics and a Master’s of Public Health from the University of Michigan\, and a Bachelor’s Degree in neuroscience from the same university. Prior to her graduate training\, she taught 7th grade science in Tulsa\, Oklahoma\, through Teach for America. At Huntsman\, Samantha also continues public health genomics work with the Department of Health focused on rural clinician education and programming. She has worked to expand cancer genetics’ role in genitourinary cancers\, and oversees the VHL Clinical Care Center.\n\nTechnical Tips to Join Meeting:\n\nThis is a web only meeting\, accessed only by your internet connection. Participants are encouraged to use the web link automatically provided after registration and to use computer speakers (and/or headsets if available) to hear the audio portion of the meeting. Please log in at least ten minutes prior to the start of the webinar.\nPlease ensure you have an updated version of Adobe Flash Player (Google Chrome has Flash built in).\nIf you are using a mobile device or tablet\, in order to view and hear the conference\, download the ReadyTalk App from your App store.\n\nDisclaimer:\nWe cannot provide individual medical advice during this webcast. Information provided in this webcast is not intended as a substitute for your physician’s guidance and care.
URL:https://liferaftgroup.org/event/lrg-webcast-genetic-testing-and-sdhx-mutations/
CATEGORIES:Education,Events,Webcast
ATTACH;FMTTYPE=image/jpeg:https://liferaftgroup.org/wp-content/uploads/2019/04/greenberg-event.jpg
ORGANIZER;CN="Sara Rothschild":MAILTO:srothschild@liferaftgroup.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20190313T120000
DTEND;TZID=America/New_York:20190313T130000
DTSTAMP:20260504T215138
CREATED:20190306T165005Z
LAST-MODIFIED:20190603T145758Z
UID:10000014-1552478400-1552482000@liferaftgroup.org
SUMMARY:LRG Webcast: The Biology of GIST
DESCRIPTION:What Every Patient Needs to Know\nWondering what in the world Gastrointestinal Stromal Tumor (GIST) is? \nJoin longtime friend of the Life Raft Group and LRG Science Team member\, Dr. David Josephy\, as he presents the basics of cell biology in cancer\, focusing on GIST. \nPresented in an easy-to-understand way\, Dr. Josephy unravels the mystery behind the differences between sarcomas and carcinomas; protein expression and the role of immunohistochemistry in diagnosis; the significance of mutations in the KIT and PDGFRA genes and the mechanism of action of tyrosine kinase inhibitor drugs. \nSound complicated? Dr. Josephy’s approachable style will decode the terminology and concepts for you\, whether you are newly diagnosed or are a long-term survivor. \nThere will be at 15 min Q&A at the end of his presentation. \n\nListen to the Webcast\n\nAbout the Presenter:\nDavid Josephy is a Professor of Molecular and Cellular Biology at the University of Guelph\, where he has taught for more than 35 years. He has been President of GIST Sarcoma Life Raft Group Canada (LRGC) since its inception in 2008. \nIn 2010\, David spent a sabbatical term working in the laboratory of Dr. Jonathan Fletcher\, a leading GIST researcher at Brigham and Women’s Hospital in Boston. \nDavid is a member of the Science Team of The Life Raft Group (USA) and collaborates with GIST patient support groups around the world. His research interests are in the field of Molecular Toxicology. He is particularly interested in the scientific basis for development of new small-molecule drugs for GIST. \n\n\nTechnical Tips to Join Meeting:\n\nThis is a web only meeting\, accessed only by your internet connection. Participants are encouraged to use the web link automatically provided after registration and to use computer speakers (and/or headsets if available) to hear the audio portion of the meeting. Please log in at least ten minutes prior to the start of the webinar.\nPlease ensure you have an updated version of Adobe Flash Player (Google Chrome has Flash built in).\nIf you are using a mobile device or tablet\, in order to view and hear the conference\, download the ReadyTalk App from your App store.\n\n\nDisclaimer:\nWe cannot provide individual medical advice during this webcast. Information provided in this webcast is not intended as a substitute for your physician’s guidance and care.
URL:https://liferaftgroup.org/event/lrg-webcast-the-biology-of-gist/
CATEGORIES:Education,Events,Webcast
ATTACH;FMTTYPE=image/jpeg:https://liferaftgroup.org/wp-content/uploads/2018/08/feature-lrg-webcast-series-rev.jpg
ORGANIZER;CN="Sara Rothschild":MAILTO:srothschild@liferaftgroup.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20180905T120000
DTEND;TZID=America/New_York:20180905T130000
DTSTAMP:20260504T215138
CREATED:20180827T180349Z
LAST-MODIFIED:20190319T185338Z
UID:10000007-1536148800-1536152400@liferaftgroup.org
SUMMARY:LRG Webcast: What is SDH...
DESCRIPTION:How Is It Related to Cancer\, and What Can Be Done About It?\nSDH is a protein that is based in the mitochondria. Its loss causes a major energy and metabolic crisis. Despite this\, some types of cells can ‘benefit’ from the loss of SDH and continue to grow uncontrollably and generate tumors. \nIdentifying metabolic enzymes as molecular drug targets that are uniquely essential for the survival of SDH-deficient cells is a key first step in the development of new therapies for SDH-deficient tumors. Some of these druggable enzymatic targets are being actively pursued. \nDr. Eyal Gottlieb will break down the biology of cells and discuss metabolism and growth during cancer formation. \nThis webcast is geared for patients and families with SDH-deficient GIST and other tumors. \nThere will be at 15 min Q&A at the end of his presentation. \nView the Webcast\n  \nTo submit questions that could potentially be addressed during the webcast\, please submit to Sara Rothschild at srothschild@liferaftgroup.org by September 1. \nFor some background on cancer metabolism\, review this document. \nPresenter\n\n\n\nDr. Eyal Gottlieb\nLaura and Isaac Perlmutter Chair of Cancer Research\, Faculty of Medicine\nTechnion – Israel Institute of Technology\nHaifa\, Israel \n\n\n\nTechnical Tips to Join Meeting:\n\nThis is a web only meeting\, accessed only by your internet connection. Participants are encouraged to use the web link automatically provided after registration and to use computer speakers (and/or headsets if available) to hear the audio portion of the meeting. Please log in at least ten minutes prior to the start of the webinar.\nPlease ensure you have an updated version of Adobe Flash Player (Google Chrome has Flash built in).\nIf you are using a mobile device or tablet\, in order to view and hear the conference\, download the ReadyTalk App from your App store.
URL:https://liferaftgroup.org/event/webcast-what-is-sdh/
CATEGORIES:Events,Webcast
ATTACH;FMTTYPE=image/jpeg:https://liferaftgroup.org/wp-content/uploads/2018/08/feature-lrg-webcast-series-rev.jpg
ORGANIZER;CN="Sara Rothschild":MAILTO:srothschild@liferaftgroup.org
END:VEVENT
END:VCALENDAR